Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 4Terminated 2Unknown 1

Sponsor Class

OTHER 19INDUSTRY 4OTHER_GOV 2NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Lymphoid 1

Conditions

Melanoma 2Lymphoma, Follicular 1Huntington Disease 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Docosahexaenoic Acids × Clear all
NCT00244816 2025-10-23

Taxoprexin® Treatment for Advanced Eye Melanoma

American Regent, Inc.

Phase 2 Completed
22 enrolled
Dermatologic

Melanoma

NCT00249262 2025-09-26

Taxoprexin Treatment for Advanced Skin Melanoma

American Regent, Inc.

Phase 2 Completed
30 enrolled
Dermatologic

Melanoma

NCT00243867 2025-08-01

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

American Regent, Inc.

Phase 3 Completed
518 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00146211 2007-12-27

TREND-HD - A Trial of Ethyl-EPA (Miraxion™) in Treating Mild to Moderate Huntington's Disease

Amarin Neuroscience Ltd

Phase 3 Completed
300 enrolled
Lymphoid

Huntington Disease, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡